On April 12, Joel was here for routine testing that indicated he was faring well. He’s scheduled to return for a positron emission tomography (PET) scan and a magnetic resonance imaging (MRI) scan on May 16.

It was PET and MRI scans that first showed Joel’s cancer was in complete remission last August, just four months after he started treatment with Yervoy at FWMOH. Additional scans in December of last year indicated the cancer was still in remission.

“That was quite a Christmas gift for us,” says Joel’s wife, Kimberly. “Joel is feeling good. He’s even able to work in the yard, although he tires easily.”

Joel’s cancer, which began as a pea-sized growth near the right-side junction of his neck and shoulder, was first diagnosed as stage 2 in 2009. The growth was removed, but Joel’s cancer manifested itself in other areas.

Joel was eventually referred to FWMOH, where his oncologist has been Dr. Matthew Carr. In February 2010, it was determined that Joel’s cancer had advanced to stage 4, terminal. Then began what have become regular visits to the world-famous Mayo Clinic in Rochester, Minnesota, where Joel has undergone additional surgeries and treatment.

Here at FWMOH last April, Joel was perhaps the first person in Indiana, and one of just a few in the whole country, to undergo treatment with Yervoy, shortly after it was approved by the Federal Drug Administration.

Yervoy is the first treatment developed specifically to treat patients with stage 4 melanoma. Patients who received treatment with Yervoy had been twice as likely to survive during both the first and second year after treatment.

Joel received four intravenous doses of Yervoy over the course of 12 weeks. While it can take up to six months for the full benefits of Yervoy to manifest, Joel experience marked improvement after just one dose.

“We’re delighted that Joel has responded so well to Yervoy,” says Dan Konow, chief operating officer for Fort Wayne Medical Oncology and Hematology. “Outcomes such as this are the reason we remain dedicated to offering our patients the latest in treatment options.”

Click here to view the Indiana’s NewsCenter story

Provenge is a biological treatment that actually uses a patient’s own immune system to fight cancer. Provenge has been proven to be a very successful treatment for certain men with advanced prostate cancer. It’s been proven to extend their lives.

“We’re very pleased to continue to be on the leading edge of cancer treatment with this radical new approach to treating prostate cancer,” says Dan Konow, chief operating officer for Fort Wayne Medical Oncology and Hematology.

Recently approved by the U.S. Food and Drug Administration, Provenge is neither a chemotherapy drug nor a form of hormone therapy to reduce testosterone level. Rather, Provenge is cellular immunotherapy designed to stimulate a patient’s immune system to identify and target prostate cancer cells. Each dose is manufactured specifically for each patient using his immune cells.

During treatment with Provenge, a patient’s white blood cells are collected, activated to seek and attack prostate cancer cells, and reintroduced into the patient’s bloodstream. Typical treatment with Provenge is completed within a month. The most common side effects are mostly mild or moderate and include chills, fatigue, fever, back pain, nausea, joint ache, and headache.

According to the American Cancer Society, prostate cancer ranks second to skin cancer as the most common cancer in American men. It’s estimated that more than 240,000 new cases will be diagnosed and that more than 28,000 men will die from prostate cancer in 2012. About one man in every six will be diagnosed with prostate cancer during his lifetime, and about one in 36 will die of the disease. Prostate cancer occurs mainly in older men, but the survival rate is high with proper treatment.

“With any cancer, it’s important to investigate every possible treatment option, and Provenge is a viable alternative treatment for men with advanced prostate cancer,” Konow says. “At the same time, Provenge is just one example of the groundbreaking treatment options we offer all our patients at Fort Wayne Medical Oncology and Hematology.”

Like so many people who discover they have cancer, Joel Saunders didn’t see it coming. Nor did he have a reason to be looking.

Joel, 46, rarely even missed a day of work, no mean feat considering he was holding down two jobs so that his wife, Kimberly, could be a stay-at-home mom for their daughter Jadyn, now 10 years old.

“Joel has always been so big, strong, and muscular—always so healthy,” Kimberly says. “He’d usually go a year or two between sick days. That’s why we were so shocked by all of this.”

It began as a pea-sized growth near the right-side junction of Joel’s neck and shoulder. He first noticed it in February 2009. The first doctor to examine the growth said it might be a swollen gland and wrote a prescription. Over the next five months, however, the abnormality grew—and grew.

In August 2009, the growth was removed. Two days later, after a biopsy was completed, Joel was told that the growth was melanoma. Joel was told his cancer was in stage 2.

Two weeks later, Joel underwent surgery to remove a host of lymph nodes to see if his cancer had metastasized, or advanced to other parts of his body. “My cancer, a very aggressive cancer—is a rare instance in which the melanoma formed inside my body,” Joel explains. “There was never a ‘source’ on my skin.”

However, Joel had spent seven years working in various capacities for a swimming pool company in Florida, where he and Kimberly met some 18 years ago. Overexposure to sunlight is the leading cause of skin cancer.

“He was always outside when he worked for that pool company,” Kimberly says. “We think that constant expose to the sun contributed to his cancer.”

Treatment begins

Joel was then referred to Fort Wayne Medical Oncology and Hematology (FWMOH), where his primary physician has been Dr. Matthew Carr. Joel first underwent treatments with interferon, a drug that boosts the immune system and fights tumors.

Still, the cancer was relentless. By February 2010, it was determined that Joel had three brain tumors, and he underwent full-brain radiation therapy in an attempt to destroy or shrink the tumors. It was also determined that Joel’s cancer had advanced to stage 4, terminal.

Soon after began what would become regular visits to the world-famous Mayo Clinic in Rochester, Minnesota, where surgeons removed Joel’s brain tumors. The first surgery was performed on Good Friday in 2010. Joel also underwent gamma-knife radiation treatments at Mayo.

“Dr. Carr was fantastic during my time at the Mayor Clinic,” Joel recalls. “He worked very closely with the doctors there, exchanging information about my condition and progress. We really appreciated that.”

Joel healed well after those surgeries, and with the addition of oral chemotherapy to his treatment at FWMOH, his condition seemed to be static. However, a fourth brain tumor was later diagnosed, and cancer was also discovered in as many as 25 places in Joel’s body.

Something new and exciting

This spring, Yervoy, a new drug, gained approval from the Federal Drug Administration. Developed by Bristol-Myers-Squibb, Yervoy prolonged the lives of people with late-stage melanoma during clinical trials.

“Yervoy is the first treatment developed specifically to treat patients with stage 4 melanoma,” Carr says. “Patients who’ve received this treatment have been twice as likely to survive during both the first and second year after treatment. That’s very exciting news.

“The body often lags in recognizing and attacking cancer cells,” Carr continues. “Yervoy, a man-made antibody, releases the emergency brake on that part of the immune system that lags behind. Then, the immune system gears up and finds and destroys melanoma cancer cells.”

Given the opportunity to try Yervoy, Joel didn’t hesitate. “We’re very thankful for the possibilities this drug presents,” Joel says. “I never gave trying it a second thought. It’s a real blessing.”

Joel is receiving a total of four doses of Yervoy at FWMOH over the course of 12 weeks. He underwent his second treatment—taken intravenously—on May 19.

“Joel may be the first person in Indiana to receive Yervoy, and one of just a few so far in the whole country,” Kimberly says. “We know his cancer can’t be cured, but it’s treatable, and Yervoy could add months to his life. And for people whose cancer is discovered early, Yervoy could add years to their lives. This is very exciting.”

While it can take up to six months for the full benefits of Yervoy to manifest, Joel has already seen positive results. After just one treatment, two protrusions on his neck all but disappeared.

As with many treatments to fight cancer, there is a potential for adverse side effects. So far, Joel has experienced a moderate version of those effects, including stomach pain and body rashes.

The best medicine

Throughout his ordeal, Joel and Kimberly have relied on family, friends, and their abiding love for each other to maintain a positive attitude. “We have a terrific support system, and Joel and I are very close,” Kimberly says. “We’re still as much in love as when we got married.

“So many things have happened over the last two years,” Kimberly continues. “We’ve been blessed so much, over and over. We continue to focus on the positive, not the negative. We think that’s a good example to set for our daughter, so when she faces difficulties in life, she’ll remember how brave her father has been.”

Faith plays a big role in fostering that positive attitude. Joel earned a bachelor’s degree in biblical studies at Cincinnati Christian University, and, following in his father’s footsteps, he once served as a minister.

Kimberly says they also have great faith in the staff at FWMOH. “They’re such good people—we feel that we’ve actually made friends at Fort Wayne Oncology. Everyone—from the receptionist when we first walked in the door—to the nurses, to the doctors, especially Dr. Carr, of course—has treated us with nothing but respect and kindness. They treat us as though Joel is the only patient they have.”

For now, Joel and Kimberly are just waiting to see what tomorrow may bring. “All we can do is have faith in God and trust in our doctors,” Joel says. “We’re just taking everything one day at a time.”

Indiana’s NewsCenter has updated its story about how Fort Wayne Medical Oncology and Hematology is using a very recently approved new drug to treat and give new hope to cancer patient Joel Saunders.

To read the updated story and view the related video, go to:

http://www.indianasnewscenter.com/home/Ft-Wayne-Cancer-Patient-Risks-Drug-Side-Effects-To-Stay-Ahead-Of-Disease-121525844.html

“Every four minutes someone new is diagnosed with a blood cancer. Every 10 minutes someone dies from a blood cancer. As an adult oncologist at Fort Wayne Medical Oncology and Hematology (FWMOH), I am aware of the devastating effects of blood cancer on both patients and their families.”

On Feb. 17^th, 2011 a competition begins, between several men in the area for the title of LLS Man of the Year.  Each dollar raised counts for one vote. He has until April 13^th, 2011 to reach his goal of raising at least $50,000.

Nattam is competing against several area men for the title of Man of the Year. Each dollar donated toward his campaign counts as one vote and goes to the Leukemia & Lymphoma Society to support cutting-edge cancer research. Whoever receives the most votes—and generates the most money for research—will be Man of the Year.

Your donation will support his campaign, help in the fight against blood cancers, as well as fund cutting-edge research to cure lymphoma, multiple myeloma and leukemia, the number one cancer killer of children. 

You may mail your tax-deductible donation, payable to The Leukemia & Lymphoma Society.  Or, if you prefer, you can log onto the campaign website to make your donation: http://in.mwoyfw.llsevent.org/nattam.

“We’re extremely pleased that Dr. Chitneni has chosen to join us,” says Dan Konow, chief operating officer for Fort Wayne Medical Oncology and Hematology. “She brings an extraordinary amount of expertise to our already-talented staff.”

Dr. Chitneni earned a medical degree at Jai Jagadhguru Murgarajendra Medical College, Kevempu University, Davangere, India.

She completed a fellowship in hematology and oncology at the Breslin Cancer Center at Michigan State University, Lansing, and served a residency at McLaren Regional Medical Center at Michigan State, Flint, where she was also chief resident in 2006–07.

Dr. Chitneni is recognized by the World Health Organization and the Medical Council of India. She’s also board-certified in internal medicine and certified by the Educational Commission for Foreign Medical Graduates.

She has also been very involved in volunteer work in India and in the United States, including her efforts on behalf of UNICEF.

Now Fort Wayne area women can conveniently donate breast tissue during a collection event at Fort Wayne Medical Oncology and Hematology, 11143 Parkview Plaza Drive, Suite 100.

Volunteers from the Komen Tissue Bank will be at Fort Wayne Medical Oncology and Hematology from 8 a.m. to 3:30 p.m. on Saturday, November 6. To reserve a spot, call (317) 274-4051.

During the donation process, a tissue sample is taken from one breast with a needle and local anesthesia. The amount of tissue taken is about one gram (or the size of two peas).

To participate, women must:

• Be age 18 or older
• Have the ability to understand and the willingness to sign an informed consent
• Be willing to give one hour of their time to complete a questionnaire and a breast biopsy
• Not be allergic to local anesthetics (numbing medicine)
• Not be receiving a therapeutic blood thinner (this does not include aspirin)
• Not have breast implants or have had a breast reduction

Runge-Helgeson made the donation because her sister-in-law recently was diagnosed with breast cancer and her mother-in-law is a two-time breast-cancer survivor.

“I knew when I went in to donate that I was doing something good, but when I left, I knew I just did something great. That is a feeling I will never forget,” Runge-Helgeson says.

By collecting samples from women with and without breast cancer, researchers will be able to determine the differences between these populations, which could lead to a better understanding of the disease. Samples taken from women without the disease are especially helpful because there are few collections of so-called “normal” specimens.

The Susan G. Komen for the Cure Tissue Bank, the first and only healthy breast-tissue bank in the world, will ultimately give researchers valuable and unprecedented research data.